Fibroblast Growth Factor 9 Inhibited Apoptosis in Random Flap via the ERK1/2-Nrf2 Pathway to Improve Tissue Survival.

Feb 13, 2023

Experts: Dupiao Zhang,Mazhar Ali Raza,Jianpeng Chen,Baolong Li,Wenbin Liu,Tao Han,Hede Yan,Liangfu Jiang

The application of random pattern skin flaps is limited in plastic surgery reconstruction due to necrosis. Fibroblast growth factor 9 (FGF9) was reported to exert a protective effect against myocardial damage and cerebral ischemia injury, but the impact of FGF9 in random flap survival is still unclear. In this study, we used a mouse model of random flaps to verify that FGF9 can directly increase flap survival area and blood flow intensity by promoting angiogenesis.
In total, 84 male C57BL/6 mice weighing between 22 and 25 g were randomly divided into three groups (n = 28 each group). After skin flap operation, one group served as a control, a treatment group received FGF9, and a treatment group received FGF9+U0126. All flap samples were incised on postoperative day 7.
Our results showed that flap survival was significantly increased in the FGF9 group compared with that in the control group. This protective function was restrained by U0126. The results of histopathology, laser Doppler, and fluorescent staining all showed significant increases in capillary count, collagen deposition, and angiogenesis. FGF9 also significantly increased the expression of antioxidant stress proteins SOD1, eNOS, HO-1, vascular marker proteins CD31, VE cadherin, and pericyte marker protein PDGFRβ. Western blot showed that the phosphorylation degree of ERK1/2 increased after FGF9 treatment, and the expression of Nrf2, a downstream factor, was u-regulated. Western blot and immunofluorescence results of apoptosis-related proteins cleaved caspase-3, BAX, and Bcl2 showed that FGF9 inhibited apoptosis. ERK inhibitor U01926 reduced the beneficial effects of FGF9 on skin flap survival, including promoting angiogenesis, and showing antiapoptosis and antioxidative stress activities.
Exogenous FGF9 stimulates angiogenesis of random flap and survival of tissue. the impact of FGF9 is closely linked to the prevention of oxidative stress mediated by ERK1/2-Nrf2. In the function of FGF9 in promoting effective angiogenesis, there may be a close interaction in the FGF9-FGFR-PDGFR-ERK-VE cadherin pathway. In particular, PDGFR and VE cadherin may interact.

Author

admin

View all posts

ABOUT THE EXPERTS

Dupiao Zhang,Mazhar Ali Raza,Jianpeng Chen,Baolong Li,Wenbin Liu,Tao Han,Hede Yan,Liangfu Jiang

Dupiao Zhang

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.

The Second School of Medicine, Wenzhou Medical University, Wenzhou 325015, China.

Mazhar Ali Raza

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.

The Second School of Medicine, Wenzhou Medical University, Wenzhou 325015, China.

Jianpeng Chen

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.

The Second School of Medicine, Wenzhou Medical University, Wenzhou 325015, China.

Baolong Li

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.

The Second School of Medicine, Wenzhou Medical University, Wenzhou 325015, China.

Wenbin Liu

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.

The Second School of Medicine, Wenzhou Medical University, Wenzhou 325015, China.

Tao Han

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.

The Second School of Medicine, Wenzhou Medical University, Wenzhou 325015, China.

Hede Yan

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.

Liangfu Jiang

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325015, China.

Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou Medical University, Wenzhou 325088, China.